Mitochondria‐targeted atovaquone promotes anti‐lung cancer immunity by reshaping tumor microenvironment and enhancing energy metabolism of anti‐tumor immune cells
Authors:
Open Access
- 6 November 2023
- journal article
- letter
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 44 (3) , 448-452
Abstract
No abstract availableFunding Information
- National Institutes of Health (R01CA223804)
- National Institutes of Health (R01CA232433)
- National Institutes of Health (R01CA205633)
- National Institutes of Health (R01CA280746)
This publication has 10 references indexed in Scilit:
- Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferationScientific Reports, 2022
- Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria‐Targeted AtovaquoneAdvanced Science, 2022
- Metabolic modeling of single Th17 cells reveals regulators of autoimmunityCell, 2021
- Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder CancerCell, 2020
- Deciphering the transcriptomic landscape of tumor-infiltrating CD8 lymphocytes in B16 melanoma tumors with single-cell RNA-SeqOncoImmunology, 2020
- Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasionScience, 2019
- Oxidative Phosphorylation as an Emerging Target in Cancer TherapyClinical Cancer Research, 2018
- Integrating single-cell transcriptomic data across different conditions, technologies, and speciesNature Biotechnology, 2018
- From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapySeminars in Cancer Biology, 2017
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005